From: Cancer incidence among Finnish male cobalt production workers in 1969–2013: a cohort study
Primary site | Employment >1 year | Employment >5 years | ||||||
---|---|---|---|---|---|---|---|---|
Obs | Exp | SIR | 95% CI | Obs | Exp | SIR | 95% CI | |
All sites | 92 | 91.9 | 1.00 | 0.81–1.22 | 77 | 71.6 | 1.08 | 0.85–1.34 |
Tongue | 3 | 0.41 | 7.39 | 1.52–21.6 | 3 | 0.30 | 10.0 | 2.06–29.2 |
Oesophagus | 2 | 1.15 | 1.74 | 0.21–6.28 | 2 | 0.89 | 2.24 | 0.27–8.08 |
Stomach | 7 | 3.47 | 2.01 | 0.81–4.15 | 5 | 2.73 | 1.83 | 0.59–4.26 |
Colon | 4 | 4.36 | 0.92 | 0.25–2.34 | 4 | 3.46 | 1.16 | 0.32–2.96 |
Rectum, rectosigmoid | 4 | 3.80 | 1.05 | 0.29–2.69 | 3 | 2.93 | 1.03 | 0.21–2.99 |
Pancreas | 2 | 3.44 | 0.58 | 0.07–2.09 | 1 | 2.69 | 0.37 | 0.01–2.07 |
Larynx, epiglottis | 2 | 0.81 | 2.45 | 0.30–8.86 | 2 | 0.65 | 3.09 | 0.37–11.2 |
Lung, trachea | 6 | 12.0 | 0.50 | 0.18–1.08 | 5 | 9.55 | 0.52 | 0.17–1.22 |
Melanoma of the skin | 1 | 3.29 | 0.30 | 0.01–1.69 | 1 | 2.53 | 0.39 | 0.01–2.20 |
Skin, non-melanoma | 3 | 2.78 | 1.08 | 0.22–3.15 | 3 | 2.22 | 1.35 | 0.28–3.94 |
Basal cell carcinoma of the skin | 18 | 19.2 | 0.94 | 0.56–1.48 | 12 | 15.1 | 0.80 | 0.41–1.38 |
Prostate | 33 | 24.4 | 1.35 | 0.93–1.89 | 26 | 19.4 | 1.34 | 0.87–1.96 |
Kidney | 2 | 3.81 | 0.52 | 0.06–1.89 | 2 | 3.00 | 0.67 | 0.08–2.40 |
Bladder and urinary tract | 9 | 4.79 | 1.88 | 0.86–3.56 | 6 | 3.76 | 1.60 | 0.59–3.47 |
Brain, central nervous system | 2 | 2.82 | 0.71 | 0.09–2.56 | 2 | 2.07 | 0.97 | 0.12–3.49 |
Thyroid gland | 2 | 0.99 | 2.01 | 0.24–7.26 | 2 | 0.72 | 2.78 | 0.34–10.0 |
Non-Hodgkin lymphoma | 3 | 4.44 | 0.68 | 0.14–1.97 | 3 | 3.42 | 0.88 | 0.18–2.56 |
Leukaemia | 3 | 2.11 | 1.42 | 0.29–4.15 | 3 | 1.58 | 1.90 | 0.39–5.54 |